GSK Hasn’t Mentioned Heart Attacks Reported in 2005 Letter
GlaxoSmithKline (GSK) neglected to mention a 2005 report involving 34 heart attacks among HIV-positive people taking abacavir (found in Ziagen, Epzicom and Trizivir) in its response to the results of a recent study finding a 90 percent increased risk of a heart attack associated with the use of the drug, according to an article today in The Independent.
The 90 percent increased risk of a heart attack among patients using abacavir, according to an analysis of data from the international Data Collection on Adverse Events on Anti-HIV Drugs (D:A:D) study, was first reported at the 15th Conference on Retroviruses and Opportunistic Infections in February in Boston. Final results were published in April in The Lancet.
When the D:A:D study results first became public, GSK responded by saying that an analysis of their studies including abacavir turned up no sign of an increased risk of a heart attack. The Independent, however, reports that physicians in Uppsala, Sweden, sent GSK a warning letter in May 2005 detailing 34 cases of heart attacks in their patients taking the nucleoside reverse transcriptase inhibitor. A statement about The Independent’s claim has not yet been released by GSK.
NEW! Scroll down to comment on this story.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
SugarandSpice43
